These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23115712)

  • 1. Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines.
    Shahkarami MK; Mokhtari Azad T; Aghaiypour K; Shafyi A; Taqavian M; Mohammadi A
    Iran Red Crescent Med J; 2012 Sep; 14(9):508-14. PubMed ID: 23115712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
    Klein NP; Abu-Elyazeed R; Povey M; Macias Parra M; Diez-Domingo J; Ahonen A; Korhonen T; Tinoco JC; Weiner L; Marshall GS; Silas PE; Sarpong KO; Ramsey KP; Fling JA; Speicher D; Campos M; Munjal I; Peltier C; Vesikari T; Baccarini C; Caplanusi A; Gillard P; Carryn S; Henry O
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):194-201. PubMed ID: 30849175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
    Nakayama T; Eda M; Hirano M; Goto W
    Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
    Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE
    Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events associated with MMR vaccines in Japan.
    Kimura M; Kuno-Sakai H; Yamazaki S; Yamada A; Hishiyama M; Kamiya H; Ueda K; Murase T; Hirayama M; Oya A; Nozaki S; Murata R
    Acta Paediatr Jpn; 1996 Jun; 38(3):205-11. PubMed ID: 8741307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
    Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
    Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection.
    Gouma S; Ten Hulscher HI; Schurink-van 't Klooster TM; de Melker HE; Boland GJ; Kaaijk P; van Els CACM; Koopmans MPG; van Binnendijk RS
    Vaccine; 2016 Jul; 34(35):4166-4171. PubMed ID: 27372154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of a study of live mumps vaccine from strain L-3 produced by the Moscow research institute for viral preparations. Characteristics of the vaccine].
    Kaptsova TI; Alekseeva AK; Gordienko NM; Rozina EE; Ermakova MN
    Vopr Virusol; 1976; (6):674-85. PubMed ID: 829008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple differentiation method of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP).
    Yoshida N; Fujino M; Ota Y; Notomi T; Nakayama T
    Vaccine; 2007 Jan; 25(7):1281-6. PubMed ID: 17097200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mumps: MMR vaccination and genetic diversity of mumps virus, 2007-2011 in Catalonia, Spain.
    Barrabeig I; Antón A; Torner N; Pumarola T; Costa J; Domínguez À;
    BMC Infect Dis; 2019 Nov; 19(1):954. PubMed ID: 31706275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
    Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
    Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.